

"soybean milk", a species which is currently being prosecuted in the parent patent application,
U.S. Serial No. 09/206,249.

Consideration of the claims as amended is respectfully requested. An early allowance is
earnestly solicited.

Respectfully submitted,



Andrea L. Colby
Attorney for Applicants
Reg. No. 30,194

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2792
March 7, 2002

APPENDIX – MARKED-UP CLAIMS

5. (Amended) The composition of claim 1 [or 3], wherein the composition comprises an agent which activates the PAR-2 pathway.
8. (Amended) The composition of claim 2 [or 4], wherein the composition comprises an agent which inhibits the PAR-2 pathway.
9. (Amended) The composition of claim 2 [or 4], wherein the composition comprises an agent selected from the group consisting of a soybean derivative and a serine protease inhibitor.
11. (Amended) The composition of claim 1, [2, 3 or 4,] wherein the appropriate cells are PAR-2-expressing cells.
16. (Amended) The composition of claim 1, [2, 3 or 4,] wherein the disorder is selected from the group consisting of a skin disorder, an immune system disorder, an inflammatory disorder, a respiratory disorder, and a central nervous system disorder.
22. (Amended) The composition of claim 1, [2, 3 or 4,] wherein the mammal is a human.
30. (Amended) The method of claim 29, wherein the agent is selected from the group consisting of [soybean milk,] soybean paste, compound I, a trypsin inhibitor, a tryptase inhibitor, a thrombin inhibitor and STI.
31. (Amended) The method of claim 23 [or 24], wherein the mammalian cell is a PAR-2-expressing cell.
36. (Amended) The method of claim 23 [or 24], wherein the mammalian cell is a human cell.
41. (Amended) The method of claim 37 [or 39], wherein the agent activates the PAR-2 pathway.
44. (Amended) The method of claim 38 [or 40], wherein the agent inhibits the PAR-2 pathway.
45. (Amended) The method of claim 38 [or 40], wherein the agent is selected from the group consisting of a soybean derivative and a serine protease inhibitor.
47. (Amended) The method of claim 37, [38, 39 or 40,] wherein the appropriate cells are PAR-2-expressing cells.

52. (Amended) The method of claim 37, [38, 39 or 40,] wherein the disorder is selected from the group consisting of a skin disorder, an immune system disorder, an inflammatory disorder, a respiratory disorder and a central nervous system disorder.

58. (Amended) The method of claim 37, [38, 39 or 40,] wherein the mammal is a human.

59. (Amended) An article of manufacture for administering to a mammal the composition of matter of claim 1, [2, 3 or 4,] comprising a solid delivery vehicle having the composition operably affixed thereto.

65. (Amended) The article of claim 64, wherein the agent is selected from the group consisting of [soybean milk,] soybean paste, Compound I, a trypsin inhibitor, a tryptase inhibitor, a thrombin inhibitor and STI.